~~<i id='F8330F92E3'><strike id='F8330F92E3'><tt id='F8330F92E3'><pre id='F8330F92E3'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：comprehensive 2025-09-28 11:22:28 Page View：8736

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： STAT Virtual Event: The State of Biosimilars: What to Watch
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Anxious about a speech? A startup wants you to pop a minty cardiac drug

APSTockThepillworkslikemagic,peoplewho’veuseditsay,toquelltheiranxietyaroundpublicspeaking.Fordecade

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

With measles on the rise, a personal story of a devastating disease

AuthorEmmiHermanstandsbehindhersister,Marcie,whosurvivedmeaslesencephalitis,assheplaysthepiano.Court